Epigenomics
Financials
Estimates*
| EUR | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | <1m | 6.2m | <1m | <1m | <1m | - | - |
| % growth | (25 %) | 637 % | (92 %) | 86 % | (70 %) | - | - |
| EBITDA | (11.1m) | (1.9m) | (11.2m) | (5.2m) | <1m | <1m | - |
| % EBITDA margin | (1315 %) | (31 %) | (2314 %) | (576 %) | 147 % | - | - |
| Profit | (11.7m) | (2.4m) | (12.0m) | (7.2m) | (<1m) | (<1m) | - |
| % profit margin | (1388 %) | (39 %) | (2479 %) | (793 %) | (216 %) | - | - |
| EV / revenue | 18.3x | -2.3x | -5.2x | 12.6x | -2.7x | - | - |
| EV / EBITDA | -1.4x | 7.5x | 0.2x | -2.2x | -1.9x | -1.5x | - |
| R&D budget | 3.7m | 3.1m | 6.2m | - | - | - | - |
| R&D % of revenue | 435 % | 50 % | 1276 % | - | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
N/A | Spinout | ||
$24.1m | Early VC | ||
| N/A | N/A | - | |
€21.0m | Series C | ||
| N/A | $41.6m | IPO | |
| N/A | €33.1m | Post IPO Equity | |
| N/A | €5.0m | Debt | |
| N/A | €4.8m | Early VC | |
€2.8m | Grant | ||
€2.8m | Grant | ||
€171m Valuation: €171m 34.2x EV/LTM Revenues | Acquisition | ||
* | N/A | Acquisition | |
| Total Funding | CAD79.9m | ||
Related Content
Recent News about Epigenomics
EditEpigenomics is a pioneering company in the healthcare sector, specializing in blood-based cancer detection. The company leverages its expertise in epigenetics, which is the study of changes in organisms caused by modification of gene expression rather than alteration of the genetic code itself. Epigenomics focuses on developing minimally invasive tests that can detect cancer through a simple blood draw, making the screening process more accessible and less daunting for patients.
The flagship product of Epigenomics is Epi proColon, a screening test designed to detect colorectal cancer early. Colorectal cancer is highly treatable if caught in its early stages, but compliance with traditional screening methods is low. Epi proColon aims to address this issue by offering a more convenient and less invasive alternative. The test is available in the U.S., South America, and Europe, broadening its reach to a global market.
Epigenomics primarily serves healthcare providers, including hospitals, clinics, and diagnostic laboratories. These clients use the company's tests to improve early cancer detection rates, thereby enhancing patient outcomes and potentially saving lives. The market for cancer diagnostics is vast and growing, driven by an aging population and increasing awareness of the importance of early detection.
The business model of Epigenomics revolves around the sale of its diagnostic tests. Revenue is generated through direct sales to healthcare providers and through partnerships with other companies in the healthcare industry. By offering a product that simplifies cancer screening, Epigenomics not only meets a critical medical need but also positions itself as a key player in the cancer diagnostics market.
In summary, Epigenomics is a healthcare company that specializes in blood-based cancer detection, serving healthcare providers globally with its innovative, minimally invasive tests. The company generates revenue through the sale of its diagnostic products, aiming to improve early cancer detection rates and patient outcomes.
Keywords: cancer detection, blood test, epigenetics, minimally invasive, colorectal cancer, healthcare, diagnostics, early detection, Epi proColon, global market.